Clinical trial
Capecitabine in Women With Operable Breast Cancer
NCT00148720 · Dana-Farber Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00148720 |
|---|---|
| Title | Capecitabine in Women With Operable Breast Cancer |
| Official title | A Phase II Study of Preoperative Capecitabine in Women With Operable Breast Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Hoffmann-La Roche Industry Beth Israel Deaconess Medical Center Brigham and Women's Hospital |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Invasive Breast Carcinoma, Primary Invasive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine |
| Enrollment | 80 |
| Start date | Sep 1, 2004 |
| Primary completion | Sep 1, 2007 |
| First posted | Sep 8, 2005 |
| Last update posted | Nov 11, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: